FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Darryle Schoepp

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Concepts & Ideas

Co-author Network

Publications

TOP 3
Rebecca A Wright; Ce Zhang; James A Monn; Craig Salhoff; Darryle D Schoepp; David O Calligaro; Bryan G Johnson; Ann E Kingston; Gerard Marek
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Darryle D Schoepp
Where will new neuroscience therapies come from?
Matthew J Fell; Kjell A Svensson; Bryan G Johnson; Darryle D Schoepp
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Darryle Schoepp (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rebecca A Wright; Ce Zhang; James A Monn; Craig Salhoff; Darryle D Schoepp; David O Calligaro; Bryan G Johnson; Ann E Kingston; Gerard Marek
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Neuropharmacology 2013;66():89-98.
2011: Darryle D Schoepp
Where will new neuroscience therapies come from?
Nature reviews. Drug discovery 2011;10(10):715-6.
2008: Matthew J Fell; Kjell A Svensson; Bryan G Johnson; Darryle D Schoepp
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
The Journal of pharmacology and experimental therapeutics 2008;326(1):209-17.
2008: Eduardo Dunayevich; Janelle Erickson; Louise Levine; Ronald Landbloom; Darryle D Schoepp; Gary D Tollefson
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(7):1603-10.
2008: P Jeffrey Conn; Carol A Tamminga; Darryle D Schoepp; Craig W Lindsley
Schizophrenia: moving beyond monoamine antagonists.
Molecular interventions 2008;8(2):99-107.
2007: Sandeep T Patil; Lu Zhang; Ferenc Martenyi; Stephen L Lowe; Kimberley A Jackson; Boris V Andreev; Alla S Avedisova; Leonid M Bardenstein; Issak Y Gurovich; Margarita A Morozova; Sergey N Mosolov; Nikolai G Neznanov; Alexander M Reznik; Anatoly B Smulevich; Vladimir A Tochilov; Bryan G Johnson; James A Monn; Darryle D Schoepp
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Nature medicine 2007;13(9):1102-7.
2007: Linda M Rorick-Kehn; Bryan G Johnson; Karen M Knitowski; Craig Salhoff; Jeffrey M Witkin; Kenneth W Perry; Kelly I Griffey; Joseph P Tizzano; James A Monn; David L McKinzie; Darryle D Schoepp
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Psychopharmacology 2007;193(1):121-36.
2007: Jeffrey M Witkin; Gerard Marek; Bryan G Johnson; Darryle D Schoepp
Metabotropic glutamate receptors in the control of mood disorders.
CNS & neurological disorders drug targets 2007;6(2):87-100.
2007: Linda M Rorick-Kehn; Bryan G Johnson; Jennifer L Burkey; Rebecca A Wright; David O Calligaro; Gerard Marek; Eric S Nisenbaum; John Catlow; Ann E Kingston; Deborah D Giera; Marc F Herin; James A Monn; David L McKinzie; Darryle D Schoepp
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
The Journal of pharmacology and experimental therapeutics 2007;321(1):308-17.
2007: James A Monn; Steven M Massey; Matthew J Valli; Steven S Henry; Gregory A Stephenson; Mark Bures; Marc Hérin; John Catlow; Deborah D Giera; Rebecca A Wright; Bryan G Johnson; Sherri L Andis; Ann E Kingston; Darryle D Schoepp
Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
Journal of medicinal chemistry 2007;50(2):233-40.
2006: Zachary A Rodd; David L McKinzie; Richard L Bell; Victoria K McQueen; James M Murphy; Darryle D Schoepp; William J McBride
The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats.
Behavioural brain research 2006;171(2):207-15.
2006: Gerard Marek; Rebecca A Wright; Darryle D Schoepp
5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740.
Neuroscience letters 2006;403(3):256-60.
2006: Anni-Maija Linden; Melvyn Baez; Marcelle Bergeron; Darryle D Schoepp
Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus.
Neuropharmacology 2006;51(2):213-28.
2006: Brianne Weiss; Andrew Alt; Ann Marie Ogden; Mary Gates; Donna K Dieckman; Amy Clemens-Smith; Ken H Ho; Keith Jarvie; Geihan Rizkalla; Rebecca A Wright; David O Calligaro; Darryle D Schoepp; Edward L Mattiuz; Robert E Stratford; Bryan Johnson; Craig Salhoff; Mary A Katofiasc; Lee A Phebus; Kathryn W Schenck; Marlene Cohen; Sandra A Filla; Paul Ornstein; Kirk W Johnson; David Bleakman
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
The Journal of pharmacology and experimental therapeutics 2006;318(2):772-81.
2006: Linda M Rorick-Kehn; Everett J Perkins; Karen M Knitowski; John C Hart; Bryan G Johnson; Darryle D Schoepp; David L McKinzie
Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
The Journal of pharmacology and experimental therapeutics 2006;316(2):905-13.
2005: John R Cirrito; Kelvin A Yamada; Mary Beth Finn; Robert S Sloviter; Kelly R Bales; Patrick May; Darryle D Schoepp; Steven M Paul; Steven Mennerick; David M Holtzman
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.
Neuron 2005;48(6):913-22.
2005: Rosario González; Iván Collado; Beatriz López de Uralde; Alicia Marcos; Luisa M Martín-Cabrejas; Concepción Pedregal; Jaime Blanco-Urgoiti; Javier Pérez-Castells; M Alejandro Fernández; Sherri L Andis; Bryan G Johnson; Rebecca A Wright; Darryle D Schoepp; James A Monn
C3'-cis-Substituted carboxycyclopropyl glycines as metabotropic glutamate 2/3 receptor agonists: synthesis and SAR studies.
Bioorganic & medicinal chemistry 2005;13(23):6556-70.
2005: Y Nie; Darryle D Schoepp; J E Klaunig; M Yard; Debomoy K Lahiri; Michael J Kubek
Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro.
Brain research 2005;1054(1):45-54.
2005: Ana Belén Bueno; Iván Collado; Alfonso de Dios; Carmen Dominguez; José Alfredo Martín; Luisa M Martín; María Angeles Martínez-Grau; Carlos Montero; Concepción Pedregal; John Catlow; D Scott Coffey; Michael P Clay; Anne H Dantzig; Terry D Lindstrom; James A Monn; Haiyan Jiang; Darryle D Schoepp; Robert E Stratford; Linda Tabas; Joseph P Tizzano; Rebecca A Wright; Marc F Herin
Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.
Journal of medicinal chemistry 2005;48(16):5305-20.
2005: Carmen Dominguez; Lourdes Prieto; Matthew J Valli; Steven M Massey; Mark Bures; Rebecca A Wright; Bryan G Johnson; Sherri L Andis; Ann E Kingston; Darryle D Schoepp; James A Monn
Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.
Journal of medicinal chemistry 2005;48(10):3605-12.
2005: Michael P Johnson; David Barda; Thomas C Britton; Renee Emkey; William J Hornback; G Erik Jagdmann; David L McKinzie; Eric S Nisenbaum; Joseph P Tizzano; Darryle D Schoepp
Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
Psychopharmacology 2005;179(1):271-83.
2005: Anni-Maija Linden; H Shannon; Melvyn Baez; Jian Liang Yu; A Koester; Darryle D Schoepp
Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Psychopharmacology 2005;179(1):284-91.
2005: Chad J Swanson; Mark Bures; Michael Johnson; Anni-Maija Linden; James A Monn; Darryle D Schoepp
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
Nature reviews. Drug discovery 2005;4(2):131-44.
2005: William J Wheeler; Dean K Clodfelter; Iván Collado; Palaniappan Kulanthaivel; Concepción Pedregal; Eli A Stoddard; Rebecca A Wright; Darryle D Schoepp
(2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptors.
Bioorganic & medicinal chemistry letters 2005;15(2):349-51.
2005: Anni-Maija Linden; Marcelle Bergeron; Darryle D Schoepp
Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo.
Neuropharmacology 2005;49 Suppl 1():120-34.
2004: Kevin Carter; Jon Dickerson; Darryle D Schoepp; Melinda Reilly; Nicole Herring; Jon Williams; Floyd R Sallee; James W Sharp; Frank R Sharp
The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis.
Neuropharmacology 2004;47(8):1135-45.
2004: David A Barda; Zhao-Qing Wang; Thomas C Britton; Steven S Henry; G Erik Jagdmann; Darrell S Coleman; Michael P Johnson; Sherri L Andis; Darryle D Schoepp
SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide.
Bioorganic & medicinal chemistry letters 2004;14(12):3099-102.
2004: Anni-Maija Linden; S J Greene; Marcelle Bergeron; Darryle D Schoepp
Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(3):502-13.
2004: Iván Collado; Concepción Pedregal; Ana Belén Bueno; Alicia Marcos; Rosario González; Jaime Blanco-Urgoiti; Javier Pérez-Castells; Darryle D Schoepp; Rebecca A Wright; Bryan G Johnson; Ann E Kingston; Eric D Moher; David W Hoard; Kelly I Griffey; Joseph P Tizzano
(2S,1'S,2'R,3'R)-2-(2'-Carboxy-3'-hydroxymethylcyclopropyl) glycine is a highly potent group 2 and 3 metabotropic glutamate receptor agonist with oral activity.
Journal of medicinal chemistry 2004;47(2):456-66.
2004: Chad J Swanson; Kenneth W Perry; Darryle D Schoepp
The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex.
Journal of neurochemistry 2004;88(1):194-202.
2003: Chad J Swanson; Darryle D Schoepp
A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists.
Annals of the New York Academy of Sciences 2003;1003():309-17.
2003: Darryle D Schoepp; Rebecca A Wright; Louise R Levine; Brenda Gaydos; William Z Potter
LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Stress (Amsterdam, Netherlands) 2003;6(3):189-97.
2003: Anni-Maija Linden; Marcelle Bergeron; Melvyn Baez; Darryle D Schoepp
Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-Fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice.
Neuropharmacology 2003;45(4):473-83.
2003: Michael P Johnson; Melvyn Baez; G Erik Jagdmann; Thomas C Britton; Thomas H Large; David O Callagaro; Joseph P Tizzano; James A Monn; Darryle D Schoepp
Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.
Journal of medicinal chemistry 2003;46(15):3189-92.
2003: Rikki N Waterhouse; Mark E Schmidt; Abida Sultana; Darryle D Schoepp; William J Wheeler; P David Mozley; Marc Laruelle
Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo.
Nuclear medicine and biology 2003;30(2):187-90.
2003: Ulrik S Sørensen; Thomas J Bleisch; Ann E Kingston; Rebecca A Wright; Bryan G Johnson; Darryle D Schoepp; Paul Ornstein
Synthesis and structure-activity relationship studies of novel 2-diarylethyl substituted (2-carboxycycloprop-1-yl)glycines as high-affinity group II metabotropic glutamate receptor ligands.
Bioorganic & medicinal chemistry 2003;11(2):197-205.
2003: Anni-Maija Linden; Melvyn Baez; Marcelle Bergeron; Darryle D Schoepp
Increased c-Fos expression in the centromedial nucleus of the thalamus in metabotropic glutamate 8 receptor knockout mice following the elevated plus maze test.
Neuroscience 2003;121(1):167-78.
2002: Chad J Swanson; Darryle D Schoepp
The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats.
The Journal of pharmacology and experimental therapeutics 2002;303(3):919-27.
2002: Ann E Kingston; Kelly I Griffey; Michael P Johnson; Mary-Jo Chamberlain; Gerald Kelly; Rosemarie Tomlinson; Rebecca A Wright; Bryan G Johnson; Darryle D Schoepp; John R Harris; Barry P Clark; Richard S Baker; Joseph T Tizzano
Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists.
Neuroscience letters 2002;330(2):127-30.
2002: Joseph P Tizzano; Kelly I Griffey; Darryle D Schoepp
The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
Pharmacology, biochemistry, and behavior 2002;73(2):367-74.
2002: Matthew Clark; Bryan G Johnson; Rebecca A Wright; James A Monn; Darryle D Schoepp
Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats.
Pharmacology, biochemistry, and behavior 2002;73(2):339-46.
2002: Darryle D Schoepp
Metabotropic glutamate receptors.
Pharmacology, biochemistry, and behavior 2002;73(2):285-6.
2002: Iván Collado; Concepción Pedregal; Angel Mazón; Juan F Espinosa; Jaime Blanco-Urgoiti; Darryle D Schoepp; Rebecca A Wright; Bryan G Johnson; Ann E Kingston
(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.
Journal of medicinal chemistry 2002;45(17):3619-29.
2002: Anni-Maija Linden; Bryan G Johnson; Steven C Peters; Harlan E Shannon; M Tian; Yi Wang; Jian Liang Yu; Anja Köster; Melvyn Baez; Darryle D Schoepp
Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor.
Neuropharmacology 2002;43(2):251-9.
2001: Darryle D Schoepp
Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.
The Journal of pharmacology and experimental therapeutics 2001;299(1):12-20.
2001: Rebecca A Wright; Macklin B Arnold; William J Wheeler; Paul Ornstein; Darryle D Schoepp
[3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.
The Journal of pharmacology and experimental therapeutics 2001;298(2):453-60.
2001: J Cartmell; Kenneth W Perry; Craig Salhoff; James A Monn; Darryle D Schoepp
Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade.
Neuropharmacology 2001;40(7):847-55.
2001: NK Thomas; Rebecca A Wright; Patrick A Howson; Ann E Kingston; Darryle D Schoepp; David E Jane
(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord.
Neuropharmacology 2001;40(3):311-8.
2001: Gerard Marek; Rebecca A Wright; Jonathan C Gewirtz; Darryle D Schoepp
A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex.
Neuroscience 2001;105(2):379-92.
2000: J Cartmell; Craig Salhoff; Kenneth W Perry; James A Monn; Darryle D Schoepp
Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum.
Brain research 2000;887(2):378-84.
2000: Rebecca A Wright; Macklin B Arnold; William J Wheeler; Paul Ornstein; Darryle D Schoepp
Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Naunyn-Schmiedeberg's archives of pharmacology 2000;362(6):546-54.
2000: Andrew J Doherty; Mary J Palmer; Zuner A Bortolotto; A Hargreaves; Ann E Kingston; Paul Ornstein; Darryle D Schoepp; David Lodge; Graham Collingridge
A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices.
British journal of pharmacology 2000;131(2):239-44.
2000: A Bond; Nicole M Jones; Caroline A Hicks; G M Whiffin; Mark A Ward; Michael F O'Neill; Ann E Kingston; James A Monn; Paul Ornstein; Darryle D Schoepp; David Lodge; Michael J O'Neill
Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo.
The Journal of pharmacology and experimental therapeutics 2000;294(3):800-9.
2000: J Cartmell; Kenneth W Perry; Craig Salhoff; James A Monn; Darryle D Schoepp
The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat.
Journal of neurochemistry 2000;75(3):1147-54.
2000: J Cartmell; Darryle D Schoepp
Regulation of neurotransmitter release by metabotropic glutamate receptors.
Journal of neurochemistry 2000;75(3):889-907.
2000: J Cartmell; James A Monn; Darryle D Schoepp
The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.
European journal of pharmacology 2000;400(2-3):221-4.
2000: J Cartmell; James A Monn; Darryle D Schoepp
Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine.
Psychopharmacology 2000;148(4):423-9.
2000: Y Chen; G Bacon; E Sher; Barry P Clark; MJ Kallman; Rebecca A Wright; Bryan G Johnson; Darryle D Schoepp; Ann E Kingston
Evaluation of the activity of a novel metabotropic glutamate receptor antagonist (+/-)-2-amino-2-(3-cis and trans-carboxycyclobutyl-3-(9-thioxanthyl)propionic acid) in the in vitro neonatal spinal cord and in an in vivo pain model.
Neuroscience 2000;95(3):787-93.
2000: J Cartmell; James A Monn; Darryle D Schoepp
Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(1):39-46.
2000: Gerard Marek; Rebecca A Wright; Darryle D Schoepp; James A Monn; George K Aghajanian
Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
The Journal of pharmacology and experimental therapeutics 2000;292(1):76-87.
1999: Bryan G Johnson; Rebecca A Wright; Macklin B Arnold; William J Wheeler; Paul Ornstein; Darryle D Schoepp
[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells.
Neuropharmacology 1999;38(10):1519-29.
1999: Darryle D Schoepp; D E Jane; James A Monn
Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
Neuropharmacology 1999;38(10):1431-76.
1999: J Cartmell; James A Monn; Darryle D Schoepp
The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
The Journal of pharmacology and experimental therapeutics 1999;291(1):161-70.
1999: Ann E Kingston; Michael J O'Neill; A Lam; K R Bales; James A Monn; Darryle D Schoepp
Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795.
European journal of pharmacology 1999;377(2-3):155-65.
1999: James A Monn; Matthew J Valli; Steven M Massey; M M Hansen; T J Kress; J P Wepsiec; A R Harkness; J L Grutsch; Rebecca A Wright; Bryan G Johnson; Sherri L Andis; Ann E Kingston; Rosemarie Tomlinson; R Lewis; K R Griffey; Joseph P Tizzano; Darryle D Schoepp
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Journal of medicinal chemistry 1999;42(6):1027-40.
1999: Ann E Kingston; Michael J O'Neill; A Bond; Valeria Bruno; Giuseppe Battaglia; F Nicoletti; J R Harris; Barry P Clark; James A Monn; David Lodge; Darryle D Schoepp
Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors.
Annals of the New York Academy of Sciences 1999;890():438-49.
1998: Stephen Fitzjohn; Zuner A Bortolotto; Mary J Palmer; Andrew J Doherty; Paul Ornstein; Darryle D Schoepp; Ann E Kingston; David Lodge; Graham Collingridge
The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity.
Neuropharmacology 1998;37(12):1445-58.
1998: Iván Collado; Jesús Ezquerra; A Mazón; Concepción Pedregal; B Yruretagoyena; Ann E Kingston; Rosemarie Tomlinson; Rebecca A Wright; Bryan G Johnson; Darryle D Schoepp
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
Bioorganic & medicinal chemistry letters 1998;8(20):2849-54.
1998: Matthew J Valli; Darryle D Schoepp; Rebecca A Wright; Bryan G Johnson; Ann E Kingston; Rosemarie Tomlinson; James A Monn
Synthesis and metabotropic glutamate receptor antagonist activity of N1-substituted analogs of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acid.
Bioorganic & medicinal chemistry letters 1998;8(15):1985-90.
1998: Darryle D Schoepp; Bryan G Johnson; Rebecca A Wright; Craig Salhoff; James A Monn
Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.
Naunyn-Schmiedeberg's archives of pharmacology 1998;358(2):175-80.
1998: Paul Ornstein; Macklin B Arnold; Thomas J Bleisch; Rebecca A Wright; William J Wheeler; Darryle D Schoepp
[3H]LY341495, a highly potent, selective and novel radioligand for labeling Group II metabotropic glutamate receptors.
Bioorganic & medicinal chemistry letters 1998;8(14):1919-22.
1998: Ana Escribano; Jesús Ezquerra; Concepción Pedregal; A Rubio; B Yruretagoyena; SR Baker; Rebecca A Wright; Bryan G Johnson; Darryle D Schoepp
(2S,4S)-amino-4-(2,2-diphenylethyl)pentanedioic acid selective group 2 metabotropic glutamate receptor antagonist.
Bioorganic & medicinal chemistry letters 1998;8(7):765-70.
1998: Paul Ornstein; Macklin B Arnold; W H Lunn; L J Heinz; J David Leander; David Lodge; Darryle D Schoepp
Heteroatom-substitution as a strategy for increasing the potency of competitive NMDA antagonists.
Bioorganic & medicinal chemistry letters 1998;8(4):389-94.
1998: DR Helton; Joseph P Tizzano; James A Monn; Darryle D Schoepp; MJ Kallman
Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
The Journal of pharmacology and experimental therapeutics 1998;284(2):651-60.
1998: Paul Ornstein; Thomas J Bleisch; Macklin B Arnold; joseph kennedy; Rebecca A Wright; Bryan G Johnson; Joseph P Tizzano; DR Helton; MJ Kallman; Darryle D Schoepp; M Hérin
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
Journal of medicinal chemistry 1998;41(3):358-78.
1998: Paul Ornstein; Thomas J Bleisch; Macklin B Arnold; Rebecca A Wright; Bryan G Johnson; Darryle D Schoepp
2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution.
Journal of medicinal chemistry 1998;41(3):346-57.
1998: Ann E Kingston; Paul Ornstein; Rebecca A Wright; Bryan G Johnson; NG Mayne; JP Burnett; R Belagaje; S Wu; Darryle D Schoepp
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
Neuropharmacology 1998;37(1):1-12.
1998: S Wu; Rebecca A Wright; P K Rockey; S G Burgett; J S Arnold; PR Rosteck; Bryan G Johnson; Darryle D Schoepp; R M Belagaje
Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells.
Brain research. Molecular brain research 1998;53(1-2):88-97.
1997: DR Helton; Joseph P Tizzano; James A Monn; Darryle D Schoepp; MJ Kallman
LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats.
Neuropharmacology 1997;36(11-12):1511-6.
1997: Vernon R J Clarke; BA Ballyk; KH Hoo; Allan Mandelzys; A Pellizzari; CP Bath; J Thomas; Erin Sharpe; Ceri H Davies; Paul Ornstein; Darryle D Schoepp; Rajender K Kamboj; Graham Collingridge; David Lodge; David Bleakman
A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission.
Nature 1997;389(6651):599-603.
1997: Giuseppe Battaglia; James A Monn; Darryle D Schoepp
In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats.
Neuroscience letters 1997;229(3):161-4.
1997: James A Monn; Matthew J Valli; Steven M Massey; Rebecca A Wright; Craig Salhoff; Bryan G Johnson; T Howe; Charles A Alt; G A Rhodes; R L Robey; K R Griffey; Joseph P Tizzano; MJ Kallman; DR Helton; Darryle D Schoepp
Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.
Journal of medicinal chemistry 1997;40(4):528-37.
1997: Darryle D Schoepp; Bryan G Johnson; Rebecca A Wright; Craig Salhoff; NG Mayne; S Wu; S L Cockerman; JP Burnett; R Belegaje; David Bleakman; James A Monn
LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.
Neuropharmacology 1997;36(1):1-11.
1996: James A Monn; Matthew J Valli; Bryan G Johnson; Craig Salhoff; Rebecca A Wright; T Howe; A Bond; David Lodge; LA Spangle; Jonathan Paschal; J B Campbell; K Griffey; Joseph P Tizzano; Darryle D Schoepp
Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase.
Journal of medicinal chemistry 1996;39(15):2990-3000.
1996: M A Desai; JP Burnett; NG Mayne; Darryle D Schoepp
Pharmacological characterization of desensitization in a human mGlu1 alpha-expressing non-neuronal cell line co-transfected with a glutamate transporter.
British journal of pharmacology 1996;118(6):1558-64.
1996: Paul Ornstein; Macklin B Arnold; N K Allen; Thomas J Bleisch; P S Borromeo; C W Lugar; J David Leander; David Lodge; Darryle D Schoepp
Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity.
Journal of medicinal chemistry 1996;39(11):2232-44.
1996: Paul Ornstein; Macklin B Arnold; N K Allen; Thomas J Bleisch; P S Borromeo; C W Lugar; J David Leander; David Lodge; Darryle D Schoepp
Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution.
Journal of medicinal chemistry 1996;39(11):2219-31.
1996: Darryle D Schoepp; Bryan G Johnson; James A Monn
(1 S,3 R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced increases in cyclic AMP formation in the neonatal rat hippocampus are mediated by a synergistic interaction between phosphoinositide- and inhibitory cyclic AMP-coupled mGluRs.
Journal of neurochemistry 1996;66(5):1981-5.
1996: R Bleakman; Darryle D Schoepp; B Ballyk; H Bufton; E F Sharpe; K Thomas; Paul Ornstein; Rajender K Kamboj
Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
Molecular pharmacology 1996;49(4):581-5.
1996: Rebecca A Wright; Darryle D Schoepp
Differentiation of group 2 and group 3 metabotropic glutamate receptor cAMP responses in the rat hippocampus.
European journal of pharmacology 1996;297(3):275-82.
1996: Camille G Wermuth; A Mann; A Schoenfelder; Rebecca A Wright; Bryan G Johnson; JP Burnett; NG Mayne; Darryle D Schoepp
(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)- pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase.
Journal of medicinal chemistry 1996;39(4):814-6.
1996: David Bleakman; B A Ballyk; Darryle D Schoepp; A J Palmer; C P Bath; E F Sharpe; M L Woolley; H R Bufton; Rajender K Kamboj; István Tarnawa; David Lodge
Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles.
Neuropharmacology 1996;35(12):1689-702.
1996: Darryle D Schoepp; Craig Salhoff; Rebecca A Wright; Bryan G Johnson; JP Burnett; NG Mayne; R Belagaje; S Wu; James A Monn
The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors.
Neuropharmacology 1996;35(12):1661-72.
1996: Darryle D Schoepp; Craig Salhoff; KS Fuson; A I Sacaan; Joseph P Tizzano; Paul Ornstein; Patrick May
Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(8-9):905-16.
1995: Paul Ornstein; Macklin B Arnold; N K Allen; J David Leander; Joseph P Tizzano; David Lodge; Darryle D Schoepp
(3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist.
Journal of medicinal chemistry 1995;38(25):4885-90.
1995: M A Desai; JP Burnett; NG Mayne; Darryle D Schoepp
Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter.
Molecular pharmacology 1995;48(4):648-57.
1995: Joseph P Tizzano; K I Griffey; Darryle D Schoepp
Receptor subtypes linked to metabotropic glutamate receptor agonist-mediated limbic seizures in mice.
Annals of the New York Academy of Sciences 1995;765():230-5; discussion 248.
1995: Darryle D Schoepp; David Lodge; David Bleakman; J David Leander; Joseph P Tizzano; Rebecca A Wright; A J Palmer; Craig Salhoff; Paul Ornstein
In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid.
Neuropharmacology 1995;34(9):1159-68.
1995: Darryle D Schoepp; Bryan G Johnson; Craig Salhoff; Matthew J Valli; M A Desai; JP Burnett; NG Mayne; James A Monn
Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4- dicarboxylate.
Neuropharmacology 1995;34(8):843-50.
1995: Joseph P Tizzano; K I Griffey; Darryle D Schoepp
Induction or protection of limbic seizures in mice by mGluR subtype selective agonists.
Neuropharmacology 1995;34(8):1063-7.
1995: Darryle D Schoepp; Bryan G Johnson; Craig Salhoff; Rebecca A Wright; J S Goldsworthy; S R Baker
Second-messenger responses in brain slices to elucidate novel glutamate receptors.
Journal of neuroscience methods 1995;59(1):105-10.
1995: Darryle D Schoepp; Joseph P Tizzano; Rebecca A Wright; A S Fix
Reversible and irreversible neuronal injury induced by intrahippocampal infusion of the mGluR agonist 1S,3R-ACPD in the rat.
Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration 1995;4(1):71-80.
1995: M A Desai; Matthew J Valli; James A Monn; Darryle D Schoepp
1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced [3H]norepinephrine release in rat hippocampal slices.
Neuropharmacology 1995;34(2):141-7.
1995: M A Desai; JP Burnett; Paul Ornstein; Darryle D Schoepp
Cyclothiazide acts at a site on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognize competitive or noncompetitive AMPA receptor antagonists.
The Journal of pharmacology and experimental therapeutics 1995;272(1):38-43.
1994: R A Wright; JOHN MCDONALD; Darryle D Schoepp
Distribution and ontogeny of 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid-sensitive and quisqualate-insensitive [3H]glutamate binding sites in the rat brain.
Journal of neurochemistry 1994;63(3):938-45.
1994: Darryle D Schoepp; J Goldsworthy; Bryan G Johnson; Craig Salhoff; S R Baker
3,5-dihydroxyphenylglycine is a highly selective agonist for phosphoinositide-linked metabotropic glutamate receptors in the rat hippocampus.
Journal of neurochemistry 1994;63(2):769-72.
1994: Dennis M Zimmerman; J S Gidda; Buddy E Cantrell; Darryle D Schoepp; Bryan G Johnson; J David Leander
Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders.
Journal of medicinal chemistry 1994;37(15):2262-5.
1994: M A Desai; JP Burnett; Darryle D Schoepp
Cyclothiazide selectively potentiates AMPA- and kainate-induced [3H]norepinephrine release from rat hippocampal slices.
Journal of neurochemistry 1994;63(1):231-7.
1994: Darryle D Schoepp
Novel functions for subtypes of metabotropic glutamate receptors.
Neurochemistry international 1994;24(5):439-49.
1994: Frank P Bymaster; David T Wong; Charles H Mitch; JS Ward; David O Calligaro; Darryle D Schoepp; Harlan E Shannon; MJ Sheardown; Preben Olesen; PD Suzdak
Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
The Journal of pharmacology and experimental therapeutics 1994;269(1):282-9.
1994: Darryle D Schoepp; W H Lunn; Craig Salhoff; JOHN MCDONALD
The NMDA receptor agonist DL-(tetrazol-5-yl)glycine is a highly potent excitotoxin.
European journal of pharmacology 1994;270(1):67-72.
1994: Rajender K Kamboj; Darryle D Schoepp; S Nutt; L Shekter; B Korczak; R A True; V Rampersad; Dennis M Zimmerman; M A Wosnick
Molecular cloning, expression, and pharmacological characterization of humEAA1, a human kainate receptor subunit.
Journal of neurochemistry 1994;62(1):1-9.
1993: Darryle D Schoepp; B G Johnson
Metabotropic glutamate receptor modulation of cAMP accumulation in the neonatal rat hippocampus.
Neuropharmacology 1993;32(12):1359-65.
1993: Joseph P Tizzano; K I Griffey; J A Johnson; A S Fix; DR Helton; Darryle D Schoepp
Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists.
Neuroscience letters 1993;162(1-2):12-6.
1993: A S Fix; Darryle D Schoepp; John W Olney; W A Vestre; K I Griffey; J A Johnson; Joseph P Tizzano
Neonatal exposure to D,L-2-amino-3-phosphonopropionate (D,L-AP3) produces lesions in the eye and optic nerve of adult rats.
Brain research. Developmental brain research 1993;75(2):223-33.
1993: JOHN MCDONALD; Darryle D Schoepp
Aminooxyacetic acid produces excitotoxic brain injury in neonatal rats.
Brain research 1993;624(1-2):239-44.
1993: JOHN MCDONALD; A S Fix; Joseph P Tizzano; Darryle D Schoepp
Seizures and brain injury in neonatal rats induced by 1S,3R-ACPD, a metabotropic glutamate receptor agonist.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1993;13(10):4445-55.
1993: Paul Ornstein; Macklin B Arnold; N K Augenstein; David Lodge; J David Leander; Darryle D Schoepp
(3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist.
Journal of medicinal chemistry 1993;36(14):2046-8.
1993: Darryle D Schoepp; B G Johnson
Pharmacology of metabotropic glutamate receptor inhibition of cyclic AMP formation in the adult rat hippocampus.
Neurochemistry international 1993;22(3):277-83.
1993: Darryle D Schoepp
The biochemical pharmacology of metabotropic glutamate receptors.
Biochemical Society transactions 1993;21(1):97-102.
1993: Darryle D Schoepp; P J Conn
Metabotropic glutamate receptors in brain function and pathology.
Trends in pharmacological sciences 1993;14(1):13-20.
1992: Donald R Gehlert; Darryle D Schoepp
Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporter.
Neurochemistry international 1992;21(4):581-4.
1992: W H Lunn; Darryle D Schoepp; David O Calligaro; R T Vasileff; L J Heinz; Craig Salhoff; P J O'Malley
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacy.
Journal of medicinal chemistry 1992;35(24):4608-12.
1992: Darryle D Schoepp; R A True
1S,3R-ACPD-sensitive (metabotropic) [3H]glutamate receptor binding in membranes.
Neuroscience letters 1992;145(1):100-4.
1992: Paul Ornstein; Darryle D Schoepp; Macklin B Arnold; N K Augenstein; David Lodge; J D Millar; J Chambers; J Campbell; Jonathan Paschal; Dennis M Zimmerman
6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists.
Journal of medicinal chemistry 1992;35(19):3547-60.
1992: L A McQuaid; Edward CR Smith; K K South; Charles H Mitch; Darryle D Schoepp; R A True; David O Calligaro; P J O'Malley; David Lodge; Paul Ornstein
Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones.
Journal of medicinal chemistry 1992;35(18):3319-24.
1992: Paul Ornstein; Darryle D Schoepp; Macklin B Arnold; N D Jones; J B Deeter; David Lodge; J David Leander
NMDA antagonist activity of (+/-)-(2SR,4RS)-4-(1H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid resides with the (-)-2R,4S-isomer.
Journal of medicinal chemistry 1992;35(17):3111-5.
1992: Rajender K Kamboj; Darryle D Schoepp; S Nutt; L Shekter; B Korczak; R A True; Dennis M Zimmerman; M A Wosnick
Molecular structure and pharmacological characterization of humEAA2, a novel human kainate receptor subunit.
Molecular pharmacology 1992;42(1):10-5.
1992: A I Sacaan; Frank P Bymaster; Darryle D Schoepp
Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine.
Journal of neurochemistry 1992;59(1):245-51.
1992: JOHN MCDONALD; Darryle D Schoepp
The metabotropic excitatory amino acid receptor agonist 1S,3R-ACPD selectively potentiates N-methyl-D-aspartate-induced brain injury.
European journal of pharmacology 1992;215(2-3):353-4.
1992: A I Sacaan; Darryle D Schoepp
Activation of hippocampal metabotropic excitatory amino acid receptors leads to seizures and neuronal damage.
Neuroscience letters 1992;139(1):77-82.
1992: Darryle D Schoepp; Bryan G Johnson; James A Monn
Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist.
Journal of neurochemistry 1992;58(3):1184-6.
1991: A I Sacaan; James A Monn; Darryle D Schoepp
Intrastriatal injection of a selective metabotropic excitatory amino acid receptor agonist induces contralateral turning in the rat.
The Journal of pharmacology and experimental therapeutics 1991;259(3):1366-70.
1991: Darryle D Schoepp; C L Smith; David Lodge; J D Millar; J David Leander; A I Sacaan; W H Lunn
D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonist.
European journal of pharmacology 1991;203(2):237-43.
1991: Darryle D Schoepp; Bryan G Johnson; R A True; James A Monn
Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)- and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis.
European journal of pharmacology 1991;207(4):351-3.
1991: Darryle D Schoepp; Bryan G Johnson; Craig Salhoff; JOHN MCDONALD; Michael V Johnston
In vitro and in vivo pharmacology of trans- and cis-(+-)-1-amino-1,3-cyclopentanedicarboxylic acid: dissociation of metabotropic and ionotropic excitatory amino acid receptor effects.
Journal of neurochemistry 1991;56(5):1789-96.
1991: Darryle D Schoepp; Bryan G Johnson
In vivo 2-amino-3-phosphonopropionic acid administration to neonatal rats selectively inhibits metabotropic excitatory amino acid receptors ex vivo in brain slices.
Neurochemistry international 1991;18(3):411-7.
1991: Darryle D Schoepp; Paul Ornstein; Craig Salhoff; J David Leander
Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist.
Journal of neural transmission. General section 1991;85(2):131-43.
1991: Paul Ornstein; Darryle D Schoepp; Macklin B Arnold; J David Leander; David Lodge; Jonathan Paschal; T Elzey
4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
Journal of medicinal chemistry 1991;34(1):90-7.
1990: Darryle D Schoepp; Paul Ornstein; J David Leander; David Lodge; Craig Salhoff; S Zeman; Dennis M Zimmerman
Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action.
The Journal of pharmacology and experimental therapeutics 1990;255(3):1301-8.
1990: Darryle D Schoepp; J Bockaert; F Sladeczek
Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors.
Trends in pharmacological sciences 1990;11(12):508-15.
1990: Darryle D Schoepp; Bryan G Johnson; Edward CR Smith; L A McQuaid
Stereoselectivity and mode of inhibition of phosphoinositide-coupled excitatory amino acid receptors by 2-amino-3-phosphonopropionic acid.
Molecular pharmacology 1990;38(2):222-8.
1990: Darryle D Schoepp; A Y Gamble; Craig Salhoff; Bryan G Johnson; Paul Ornstein
Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes.
European journal of pharmacology 1990;182(3):421-7.
1989: Darryle D Schoepp; Bryan G Johnson
Inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the neonatal rat hippocampus by 2-amino-3-phosphonopropionate.
Journal of neurochemistry 1989;53(6):1865-70.
1989: R J Secrest; Darryle D Schoepp; Marlene L Cohen
Comparison of contractions to serotonin, carbamylcholine and prostaglandin F2 alpha in rat stomach fundus.
The Journal of pharmacology and experimental therapeutics 1989;250(3):971-8.
1989: Darryle D Schoepp; Bryan G Johnson
Comparison of excitatory amino acid-stimulated phosphoinositide hydrolysis and N-[3H]acetylaspartylglutamate binding in rat brain: selective inhibition of phosphoinositide hydrolysis by 2-amino-3-phosphonopropionate.
Journal of neurochemistry 1989;53(1):273-8.
1989: Darryle D Schoepp
Protein kinase C-mediated inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the neonatal rat hippocampus.
Neurochemistry international 1989;15(2):131-6.
1989: Darryle D Schoepp; Craig Salhoff; C C Hillman; Paul Ornstein
CGS-19755 and MK-801 selectively prevent rat striatal cholinergic and gabaergic neuronal degeneration induced by N-methyl-D-aspartate and ibotenate in vivo.
Journal of neural transmission. General section 1989;78(3):183-93.
1988: Darryle D Schoepp; Bryan G Johnson
Selective inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the rat hippocampus by activation of protein kinase C.
Biochemical pharmacology 1988;37(22):4299-305.